Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2014-04-28 Annual Report
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
ThromboGenics_002_FinVerslag_010_EN_singles.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report' and contains comprehensive financial statements, consolidated annual accounts, management reports, and auditor reports for the fiscal year 2013. It meets the criteria for a full annual report as it provides detailed financial performance, governance information, and operational history, rather than being a mere announcement or summary. FY 2013
2014-04-28 English
ThromboGenics_002_FinVerslag_015_NL_singles.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag' (Annual Report) for the year 2013. It contains a comprehensive table of contents covering consolidated financial statements, management reports, governance information, and auditor reports. It is clearly the full annual report document, not an announcement or summary, as it includes detailed financial tables (balance sheet, income statement) and management commentary. Therefore, it is classified as a 10-K (Annual Report). FY 2013
2014-04-28 Dutch
ThromboGenics_002_FinVerslag_015_NL_singles.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag' (Annual Report) for the year 2013. It contains a comprehensive table of contents covering consolidated financial statements, management reports, governance information, and auditor reports. It is clearly the full annual report document, not an announcement or summary, as it includes detailed financial tables (balance sheet, income statement) and management commentary. Therefore, it is classified as a 10-K (Annual Report). FY 2013
2014-04-07 Dutch
Volmacht.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'VOLMACHT' (Proxy) and contains detailed instructions and sections for shareholders to appoint a representative ('de gevolmachtigde') for the 'jaarvergadering' (annual general meeting). The agenda items confirm this is related to an AGM, covering the review of the annual report, approval of remuneration reports, discharge of directors, and reappointment of directors. This document is the formal proxy form used to grant voting rights for the AGM, which falls under the category of materials shared during the Annual General Meeting.
2014-04-07 Dutch
Controleverslag Commissaris Statutaire Jaarrekening.pdf
Audit Report / Information Classification · 99% confidence The document is titled 'Verslag van de commissaris aan de algemene vergadering over het boekjaar afgesloten op 31 december 2013' (Report of the commissioner to the general meeting concerning the financial year ended December 31, 2013). It contains an 'Oordeel zonder voorbehoud' (Unqualified opinion) on the annual accounts and discusses compliance with legal and statutory requirements, which are the core components of an independent auditor's report. This clearly indicates it is an Audit Report/Information document, as it focuses on the audit findings for the past fiscal year, rather than being the full Annual Report (10-K) or a mere announcement of a report (RPA). Therefore, the appropriate code is AR (Audit Report / Information). FY 2013
2014-04-07 Dutch
Jaarverslag RvB Statutaire Jaarrekening.pdf
Annual Report Classification · 100% confidence The document is a 'Jaarverslag van de Raad van Bestuur' (Annual Report of the Board of Directors) for ThromboGenics NV for the fiscal year 2013. It contains detailed financial performance data, including profit/loss statements, revenue breakdowns, operational costs, capital structure changes, risk assessments, and governance disclosures (conflicts of interest). As it is a comprehensive annual report containing substantive financial statements and management analysis, it is classified as an Annual Report (10-K). FY 2013
2014-04-07 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.